Fertitta Entertainment is on the brink of finalizing an acquisition deal for Caesars Entertainment valued at nearly $18 billion. This development follows a lengthy bidding conflict with billionaire investor Carl Icahn, which began in January and culminated last week. Recent filings from Caesars provide a detailed account of the intense competition to seize control of the casino giant.
The agreement with Fertitta, announced in May at a price of $17.6 billion, involves a payment of $31 per share. Despite Icahn making several higher offers during the agreed-upon "go shop" phase, it seems that Fertitta's bid is set to proceed without further contest.
Should this deal not close by June next year, Fertitta will incur a daily ticking fee per share. Moreover, the Texas-based company led by Tilman Fertitta would face a penalty of $450 million if it withdraws from the agreement, while Caesars would owe a $200 million penalty should it back out.
Icahn, 90 years old, persisted with his pursuit, submitting a final proposal of $34 per share in July. However, Caesars declined this offer citing complications regarding debt financing. The company extended the opportunity for Icahn to adjust his offer until August 10, but no substantial progress was achieved.
The Caesars board has since backed Fertitta’s proposal, with plans to hold a shareholder meeting soon to vote on the acquisition. Additionally, the deal is subject to regulatory review but received a positive signal last month when the Nevada Gaming Commission unanimously approved the necessary amendments to permits and registrations.
The bidding war that began in January was ignited by Icahn, who made his first non-binding offer of $28.50 per share on January 2. Fertitta entered the fray shortly after with a bid of $28.75 per share, but both were promptly rejected by Caesars' board.
As the bidding progressed:
– On January 29, Fertitta increased its offer to $30.50 per share.
– Icahn responded with a bid of $32.00 on February 5.
– Fertitta countered swiftly with $31.50 per share by February 6, later matching Icahn's $32.00 offer on February 13.
– By February 20, Caesars entered into an Exclusivity Agreement with Fertitta, effectively halting other offers.
– Icahn continued to push with an unsolicited offer of $33.00 on February 28, which led to further negotiations but ultimately stalled.
In April, a mysterious "Party B" group presented an offer between $36 and $37 per share, which Caesars could not verify. Following that, Fertitta reduced their offer back to $31 per share due to rising financing costs and economic uncertainties.
Throughout May, Caesars countered with minor adjustments, yet Fertitta remained firm on $31. Eventually, the two parties reached a definitive Merger Agreement on May 27. After Icahn’s later bid of $34 per share, which included $6.5 billion in new debt financing suggested through Jefferies, the financing proposal faced issues, exacerbating concerns over the terms.
Icahn's offer was hinged on the Carano family's equity rollover and negotiations with existing management to address control changes concerning the company’s debt. While the family was willing to roll over 5 million of their shares in Fertitta's proposal, they were apprehensive about Icahn’s offer. Following their refusal, he proposed reducing his financing by $1 billion to entice support, yet Caesars' board remained unconvinced.
The board eventually indicated that it had to limit further discussions with Icahn and requested the return of all confidential materials.
Icahn has a historical connection with Caesars, having acquired a significant stake in the company in 2019 and contributing to Eldorado's subsequent acquisition, which established the leadership team currently in place, including CEO Tom Reeg and the Carano family. Though he divested shares after that deal, he began purchasing stakes again in May 2024 under an agreement to limit his ownership in exchange for board representation.
Despite Icahn's longstanding ties and negotiations with current management throughout 2025, the emergence of Fertitta's offer in December marked a turning point, leading to the enduring competition which now seems poised for its conclusion, contingent on regulatory approval.
